Evotec SE (EVO) Financials

EVO Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 2.4 billion 1.2 billion
2023-06-30 2.5 billion 1.2 billion
2023-03-31 2.5 billion 1.2 billion
2022-12-31 2.4 billion 1.1 billion

EVO Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -26.6 million ?
2023-06-30 -59.6 million ?
2023-03-31 -62.9 million 10.8 million
2022-12-31 -61.9 million ?

EVO Net Income

No data available :(

EVO Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 655.5 million - -
2023-06-30 688.3 million - -
2023-03-31 795.7 million - -
2022-12-31 783.4 million - 189.8 million

EVO Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 374.6 million
2023-06-30 384.8 million
2023-03-31 385.2 million
2022-12-31 379.2 million

EVO Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 48.6 million 18.5 million 41.6 million -
2023-06-30 56.6 million 13.5 million 49.6 million -
2023-03-31 26.3 million 23.2 million - -
2022-12-31 25.9 million 22.9 million 49.7 million -

EVO Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 207.8 million 167.7 million
2023-06-30 185.2 million 134.8 million
2023-03-31 262.4 million 172.5 million
2022-12-31 258.3 million 169.8 million

EVO

Price: $5.27

52 week price:
5.02
13.49

Payout Ratio Range:
53.60%
96.32%

Earnings Per Share: -0.29 USD

P/E Ratio: -26

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 14985

Market Capitalization: 2.7 billion

Average Dividend Frequency: 12

Links: